Healius Limited

Equities

HLS

AU0000033359

Healthcare Facilities & Services

Market Closed - Australian S.E. Other stock markets 11:40:52 03/06/2024 am IST			5-day change	1st Jan Change
1.33 ^AUD	+4.72%		+2.31%	-18.65%

28/05	Private Equity Reportedly Eyes Healius Diagnostic Imaging Unit	CI
27/05	Healius Hires UBS to Sell Lumus Imaging	MT

Healius Limited Provides Earnings Guidance for the Year Ended June 30, 2020

July 27, 2020 at 05:05 am IST

Healius Limited provided earnings guidance for the year ended June 30, 2020. For the period, the company expects underlying EBIT of approximately $102 to $104 million and underlying NPAT of approximately $54 to $56 million from continuing operations.

Latest news about Healius Limited

Private Equity Reportedly Eyes Healius Diagnostic Imaging Unit	28/05	CI
Healius Hires UBS to Sell Lumus Imaging	27/05	MT
Healius Provides Updates on Strategic Review	27/05	CI
Healius Refinances Debt Facility to March 2027	14/05	MT
Healius Brings in UBS as It Reviews Strategy, Considers Asset Sales	12/03	CI
Morgan Stanley Adjusts Healius’ Price Target to AU$1 From AU$1.30, Keeps at Underweight	06/03	MT
Australia shares inch lower as miners weigh; GDP data in focus	05/03	RE
Healius Accelerates Strategic Review	05/03	CI
Jarden Research Adjusts Healius’ Price Target to AU$1.26 From AU$1.29, Keeps at Underweight	28/02	MT
Australian Shares Inch Up as Market Awaits Economic Data, US Fed Statements	27/02	MT
Healius Shares Sink 6%; Reports 2% Decline in H1 FY24 Revenue, Widens Net Loss	27/02	MT
Healius Limited Provides Earnings Guidance for Second Half of 2024 and Fiscal Year 2024	27/02	CI
Transcript : Healius Limited, H1 2024 Earnings Call, Feb 27, 2024	27/02
Healius Reports 2% Decline in H1 FY24 Revenue, Widens Net Loss	27/02	MT
Healius Reports Wider H1 FY24 Loss as Revenue Slips 2%	27/02	MT
Healius Limited Reports Earnings Results for the Half Year Ended December 31, 2023	27/02	CI
Healius Subsidiary Enters Commercial Deal with Geneva-based SGS	06/02	MT
Australian shares on three-day winning streak; banks, miners lead	23/01	RE
Australia shares starts 2024 higher on rate-cut hopes	02/01	RE
Australian Clinical Labs Gets Regulator Approval to Withdraw Healius Takeover Offer	26/12	MT
Australian Clinical Labs Limited cancelled the acquisition of Healius Limited from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others.	22/12	CI
Australian shares end higher on miners, Fed rate pivot	15/12	RE
US Fed's Dovish Stance Lifts Australian Shares	15/12	MT
Australian Clinical Labs Intends to Withdraw Proposed Healius Takeover	15/12	MT
Competition Regulator Denies Australian Clinical Labs’ Proposed Takeover of Healius	15/12	MT

Chart Healius Limited

Duration

Period

More charts

Company Profile

Healius Limited is a healthcare company. The Companyâs segments include Pathology, Imaging and Other. The Pathology segment is a provider of pathology services, including specialty pathology and clinical trials. The Imaging segment provides imaging services from standalone imaging sites, hospitals and medical centers. It has a network of pathology laboratories, collection centers and diagnostic imaging centers. It provides specialty diagnostic services to consumers and their referring practitioners. Its brands include Laverty Pathology, QML Pathology, Dorevitch Pathology, Western Diagnostic Pathology, Genomic Diagnostics, Abbott Pathology, IQ Pathology, Vetnostics, TML Vetnostics, Agilex Biolabs, Lumus Imaging, and others. Its Pathology operates 100 medical laboratories and 2,000 patient collection centers across metropolitan, regional and remote Australia. IQ Pathology is a specialized dermatopathology laboratory that provides comprehensive dermatopathology services Australia wide.

Sector

Healthcare Facilities & Services

Calendar

21/08/2024 - Q4 2024 Earnings Release (Projected)

Related indices

S&P/ASX 200

More about the company

Income Statement Evolution

More financial data

Ratings for Healius Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

1.27 AUD

Average target price

1.372 AUD

Spread / Average Target

+8.02%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
HEALIUS LIMITED	-18.65%	612M
SONIC HEALTHCARE LIMITED	-24.66%	7.76B
RADNET, INC.	+68.65%	4.33B
SYNLAB AG	-3.33%	2.64B
DR. LAL PATHLABS LIMITED	+3.74%	2.63B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-46.17%	2.16B
NEOGENOMICS, INC.	-15.27%	1.75B
FLEURY S.A.	-20.01%	1.46B
METROPOLIS HEALTHCARE LIMITED	+13.62%	1.17B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-43.81%	1.14B

Medical & Diagnostic Laboratories